Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment.
The NeuroMotor Pen (NMP) is a unique, patented and CE-marked system which combines multiple sensors built into a digital pen with software for administering standardised tasks and a cloud-based analytical engine with a decision support system. The device enables users to record non-invasively and analyse parameters of minute limb and hand motion, enabling quantification of fine motor skill. These parameters are used as ‘digital biomarkers’ to provide objective information to clinicians about movement abnormalities, thus supporting diagnosis and monitoring of Parkinson’s Disease and other neuromotor impairments.
As a monitoring (symptoms tracking) tool, the NeuroMotor Pen provides objective and accurate measurements with automated record keeping. It provides a quick, non-invasive and objective aid to diagnosis, providing a low-cost alternative to brain scans. The improved accuracy over other solutions provides advantages – in particular for measuring response to dopaminergic medication. There are currently no other devices on the market that can measure fine motor skill with the same level of accuracy.
As the only digital diagnostic for Parkinson’s Disease on the market, the disruptive technology can aid in timely diagnostic decision making, leading to improved efficiencies in the pathway with potentially better long term clinical outcomes and reduced costs.
Rutger Zietsma, CEO said: “We are delighted to be joining the ABHI UK Pavilion at MEDICA, where we will be launching our innovative technology designed to radically improve patient diagnosis of Parkinson’s and other neuromotor impairments. Using the NeuroMotor Pen can offer a direct cost reduction for disease diagnosis as a replacement for more expensive methods. The product can assist with a timely, accurate diagnosis, increasing early treatment. Moreover, it can assist with treatment optimisation through symptom tracking, which for many patients can delay deterioration to the stage where interventions and long-term care costs increase. We look forward to meeting new partners and distributors at the event.”
Clinical trials and over 10 years of research have demonstrated that the NeuroMotor Pen detects these early signs with high accuracy of over 80% and high sensitivity. The device is implemented both in primary care to support specialist referral decision making as well as Parkinson’s specialist services to support diagnostic and patient monitoring activities.
Manus Neurodynamica Ltd is also trialing future product versions for assessment of extrapyramidal adverse effects of antipsychotic drugs that has the potential to optimize treatment and reduce side effects. In addition, a product is in development that combines cognitive assessment with motor skill assessment with applications in early detection of dementia. Only around 68% of over 65’s estimated to have dementia have been diagnosed. Early identification is recognised as substantially increasing the chance of maintaining functional abilities and deferring the point of escalation, where additional care and support is required at home or in a care facility. New screening technologies are required to correctly
identify affected patients.
Paul Benton, Managing Director, International at the ABHI added: “Early diagnosis and timely access to specialist care is vital for patients, and Manus’s revolutionary technology is helping to make this a reality for patients with dementia. We are delighted that they have chosen to launch their innovative device on the ABHI Pavilion. We look forward to supporting them at MEDICA.”
MEDICA is taking place from 15 – 18 November 2021 and throughout the show, Manus will be located on the ABHI UK Pavilion – Hall 16 Stand K42. For more information, visit
ABHI is the UK’s leading industry association for health technology (HealthTech).
ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS, and regulators.
HealthTech plays a key role in supporting the delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is now the largest employer in the broader Life Sciences sector, employing 121,000 people in 3,500
companies, with a combined turnover of £22.2bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 300 members account for approximately 80% of the sector by value.
About Manus Neurodynamica – www.manusneuro.com
Dr Rutger Zietsma founded Manus in August 2008. The Company’s main activity is designing,
patenting and marketing innovative technologies used in medical devices and personal care products which have the capability to improve people’s health and wellbeing. The Company implements quality procedures to medical standards.
Its principal product is the NeuroMotor PenTM designed for use in the diagnosis and monitoring of neuromotor impairments. The pen particularly focuses on patients with Parkinson’s disease and uses limb and hand motion to diagnose patients quickly and non-invasively. It has
applications across not just diagnosis but also screening, monitoring, rehabilitation and drug
development for a number of different movement disorders.
About NeuroMotor PenTM
NeuroMotor Pen™ (NMP) is a unique, patented and CE-marked system that combines sensor
technologies built into a digital pen with software and an analytical engine with Decision
Support System. The interface enables users to record non-invasively and analyse
parameters of minute limb and hand motion. This enables quantification of fine motor skill.
These parameters are used as ‘digital biomarkers’ to provide objective information about movement abnormalities. NMP can be used to support diagnosis and monitoring of
Parkinson’s Disease and other neuromotor impairments. It has the potential to be a quick,
inexpensive, non-invasive, and objective aid to diagnosis that can provide a low-cost
alternative to brain scans.